|
PRESS RELEASE
FOR IMMEDIATE RELEASE
CONTACT
INVITRO INTERNATIONAL POSTS
3RD CONSECUTIVE PROFITABLE QUARTER
Company also receives Corrositex endorsement from government sponsored
science panel
| Irvine, CA
August 3, 1999 -- Invitro International (OTC IVRO) announced
that its third quarter ended June 30, 1999 produced sales
revenues of $150,060 and net income of $5,700. Fiscal 1999
year to date sales of nearly $479,000 are 17½% ahead of 1998
with the income total of $49,083 comparing favorably to a
loss of $184,073 in the prior year.
In other important company news, InVitro announced that
it had received an endorsement for its product Corrositex
from a federally appointed panel of scientists (National
Institute of Environmental Health Sciences) for use in evaluating
potential skin corrosivity and irritation from chemicals
and chemical formulations. Corrositex is the first such
non-animal test method product endorsed by a U.S. government
body. The panel review suggests that Corrositex testing
can fully replace the use of animals for testing corrosiveness
and irritation in some cases, while in others a tiered testing
approach may be employed, thus having the potential to reduce
considerably the numbers of laboratory animals used. This
approach also has the potential to lower industry testing
costs. IVRO President & CEO, W. Richard Ulmer, said "We
are delighted and proud that our Corrositex test method
can lead the way to lowering chemical, cosmetic, and other
industry costs, save these companies time in their new product
development cycles, and offers a bit of a good feeling for
everyone when fewer animals are used in testing overall.
We know that over 2000 new chemicals are introduced each
year, and of course there are even more new cosmetic and
over the counter personal products; our task now is to use
our added new credibility to inform these manufacturers
of how InVitro's several non-animal test methods can help
them."
|
|
CONDENSED
CONSOLIDATED STATEMENT OF OPERATIONS
|
| |
Three months ended
June 30 |
Nine months ended June 30
|
| |
1999
|
1998
|
1999
|
1998
|
| Revenues |
150,060
|
138,557
|
478,711
|
407,574
|
| Costs and expenses |
152,074
|
230,170
|
446,914
|
593,148
|
| Income (loss) from operations
|
(2014)
|
(36,000)
|
31,797
|
(185,574)
|
| Other income (loss) |
7,751
|
950
|
17,286
|
1,501
|
| Net income (loss) |
5,737
|
(90,663)
|
49,083
|
(184,073)
|
| Income (loss) per common share
|
0.0004
|
(0.0100)
|
0.0034
|
(0.0131)
|
Weighted average common
shares outstanding |
14,453,300
|
14,023,300
|
14,453,300
|
14,023,300
|
| |
|
CONDENSED
CONSOLIDATED BALANCE SHEET
|
| |
|
|
June 30, 1999
|
Sep 30, 1998
|
| |
(UNAUDITED)
|
|
| Cash, cash equivalents
and marketable securities |
75,050
|
59,960
|
| Other current assets |
|
|
223,302
|
268,571
|
| Total current assets |
|
|
298.352
|
328,531
|
| Noncurrent assets |
|
|
203,641
|
154,479
|
| Total assets |
|
|
501,993
|
483.010
|
| Current liabilities |
|
|
21,678
|
54,856
|
| Shareholders' equity |
|
|
480,315
|
428,154
|
| Total liabilities and equity
|
|
|
501,993
|
483,010
|
InVitro International
17751 Sky Park East, Suite G
Irvine, CA 92614
800-2-INVITRO (800-246-8487)
949-851-8356 (International callers)
949- 851-4985 Fax
invitro@invitrointl.com
|
|